Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer... Show more
KURA is expected to report earnings to fall 74.02% to -22 cents per share on March 03
Q4'25
Est.
$-0.22
Q3'25
Missed
by $0.10
Q2'25
Missed
by $0.34
Q1'25
Missed
by $0.04
Q4'24
Beat
by $0.35
The last earnings report on November 04 showed earnings per share of -85 cents, missing the estimate of -75 cents. With 5.32M shares outstanding, the current market capitalization sits at 929.35M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. KURA showed earnings on November 04, 2025. You can read more about the earnings report here.